ISPOR - BRCA1/2-Mutated Breast Cancer In Select EU Markets- Incidence, Treatable Populations, And Potential Market Size For Parp Inhibitors

Full Text

BRCA1/2-Mutated Breast Cancer In Select EU Markets- Incidence, Treatable Populations, And Potential Market Size For Parp Inhibitors

Abstract

Authors

A Isherwood A Duval N Parihar

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now